Abstract
The treatment of immune-mediated inflammatory diseases (IMIDs) is one of the main challenges of modern medicine. Although a number of disease-modifying antirheumatic drugs (DMARDs) are available, there is wide variability in clinical response to treatment among individuals. Therapeutic drug monitoring (TDM) has been proposed to optimize treatment; however, some patients still experience unsatisfactory outcomes, although the blood concentrations of drugs in these patients remain in the therapeutic range. One possible reason for this is that the conventional samples (e.g., whole blood or plasma) used in TDM may not accurately reflect drug concentrations or concentrations of their metabolites at the target site. Hence, more refined TDM approaches to guide clinical decisions related to dose optimization are necessary. Circulating leukocytes or white blood cells have a critical role in driving the inflammatory process. They are recruited to the site of injury, infection and inflammation, and the main target of small molecule DMARDs is within immune cells. Given this, assaying drug concentrations in leukocytes has been proposed to be of possible relevance to the interpretation of outcomes. This review focuses on the clinical implications and challenges of drug monitoring of DMARDs in peripheral blood leukocytes from therapeutic or toxicological perspectives in IMIDs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
All data are included in this manuscript.
References
Adedokun OJ, Xu Z, Gasink C, Jacobstein D, Szapary P, Johanns J, Gao LL, Davis HM, Hanauer SB, Feagan BG, Ghosh S, Sandborn WJ (2018) Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn’s disease. Gastroenterology 154:1660–1671. https://doi.org/10.1053/j.gastro.2018.01.043
Amos RS, Pullar T, Bax DE, Situnayake D, Capell HA, McConkey B (1986) Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years. Br Med J (clin Res Ed) 293:420–423. https://doi.org/10.1136/bmj.293.6544.420
Angelis-Stoforidis P, Vajda FJ, Christophidis N (1999) Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin Exp Rheumatol 17:313–320
Astbury C, Taggart AJ, Juby L, Zebouni L, Bird HA (1990) Comparison of the single dose pharmacokinetics of sulphasalazine in rheumatoid arthritis and inflammatory bowel disease. Ann Rheum Dis 49:587–590. https://doi.org/10.1136/ard.49.8.587
Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentré F, Taburet AM (2010) Intracellular Pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin Pharmacokinet 49:17–45. https://doi.org/10.2165/11318110-000000000-00000
Becker ML (2015) Using methotrexate metabolites to make clinical decisions in JIA. Curr Treat Options Rheumatol 1:381–395. https://doi.org/10.1007/s40674-015-0028-1
Belaiche J, Desager JP, Horsmans Y, Louis E (2001) Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol 36:71–76. https://doi.org/10.1080/00365520150218084
Bergan S, Bentdal O, Sødal G, Brun A, Rugstad HE, Stokke O (1997) Patterns of azathioprine metabolites in neutrophils, lymphocytes, reticulocytes, and erythrocytes: relevance to toxicity and monitoring in recipients of renal allografts. Ther Drug Monit 19:502–509. https://doi.org/10.1097/00007691-199710000-00003
Blanchet B, Jallouli M, Allard M, Ghillani-Dalbin P, Galicier L, Aumaitre O, Chasset F, Le Guern V, Liote F, Smail A, Limal N, Perard L, Desmurs-Clavel H, Le Thi Huong D, Asli B, Kahn JE, Sailler L, Ackermann F, Papo T, Sacre K, Fain O, Stirnemann J, Cacoub P, Leroux G, Cohen-Bittan J, Sellam J, Mariette X, Goulvestre C, Hulot JS, Amoura Z, Vidal M, Piette JC, Group C, Jourde-Chiche N, Costedoat-Chalumeau N (2020) Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence. Arthritis Res Ther 22:223. https://doi.org/10.1186/s13075-020-02291-z
Bonelli M, Scheinecker C (2018) How does abatacept really work in rheumatoid arthritis? Curr Opin Rheumatol 30:295–300. https://doi.org/10.1097/bor.0000000000000491
Brady K, Alexander RV, Stimson D, Rudolph M, Kammesheidt A (2021) Capillary blood levels of hydroxychloroquine and methotrexate are stable for up to 5 years when collected on volumetric absorptive microsamplers. J Appl Lab Med 6:858–867. https://doi.org/10.1093/jalm/jfaa221
Brocks DR, Skeith KJ, Johnston C, Emamibafrani J, Davis P, Russell AS, Jamali F (1994) Hematologic disposition of hydroxychloroquine enantiomers. J Clin Pharmacol 34:1088–1097. https://doi.org/10.1002/j.1552-4604.1994.tb01986.x
Brown PM, Pratt AG, Isaacs JD (2016) Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol 12:731–742. https://doi.org/10.1038/nrrheum.2016.175
Carlsson H, Hjorton K, Abujrais S, Ronnblom L, Akerfeldt T, Kultima K (2020) Measurement of hydroxychloroquine in blood from SLE patients using LC-HRMS-evaluation of whole blood, plasma, and serum as sample matrices. Arthritis Res Ther 22:125. https://doi.org/10.1186/s13075-020-02211-1
Chan V, Charles BG, Tett SE (2005) Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis. Br J Clin Pharmacol 60:257–264. https://doi.org/10.1111/j.1365-2125.2005.02415.x
Chapdelaine A, Mansour AM, Troyanov Y, Williamson DR, Dore M (2017) Metabolite monitoring to guide thiopurine therapy in systemic autoimmune diseases. Clin Rheumatol 36:1341–1348. https://doi.org/10.1007/s10067-017-3554-4
Chen Z (2018) What’s new about the mechanism of methotrexate action in psoriasis? Br J Dermatol 179:818–819. https://doi.org/10.1111/bjd.16908
Costedoat-Chalumeau N, Amoura Z, Hulot JS, Hammoud HA, Aymard G, Cacoub P, Francès C, Wechsler B, du Huong LT, Ghillani P, Musset L, Lechat P, Piette JC (2006) Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 54:3284–3290. https://doi.org/10.1002/art.22156
Cunha C, Alexander S, Ashby D, Lee J, Chusney G, Cairns TD, Lightstone L (2018) Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome? Nephrol Dial Transplant 33:1604–1610. https://doi.org/10.1093/ndt/gfx318
Dalrymple JM, Stamp LK, O’Donnell JL, Chapman PT, Zhang M, Barclay ML (2008) Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 58:3299–3308. https://doi.org/10.1002/art.24034
Daraghmeh DN, Moghaddami M, Bobrovskaya L, Proudman SM, Wiese MD (2022) Quantitation of methotrexate polyglutamates in human whole blood, erythrocytes and leukocytes collected via venepuncture and volumetric absorptive micro-sampling: a green LC-MS/MS-based method. Anal Bioanal Chem 414:6029–6046. https://doi.org/10.1007/s00216-022-04186-1
Das KM, Dubin R (1976) Clinical pharmacokinetics of sulphasalazine. Clin Pharmacokinet 1:406–425. https://doi.org/10.2165/00003088-197601060-00002
Dollery CT (2013) Intracellular drug concentrations. Clin Pharmacol Ther 93:263–266. https://doi.org/10.1038/clpt.2012.240
Dubinsky MC (2004) Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol 2:731–743. https://doi.org/10.1016/s1542-3565(04)00344-1
Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Théorêt Y, Seidman EG (2000) Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118:705–713. https://doi.org/10.1016/s0016-5085(00)70140-5
Duley JA, Florin TH (2005) Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides. Ther Drug Monit 27:647–654. https://doi.org/10.1097/01.ftd.0000169061.52715.3e
El-Gabalawy H, Guenther LC, Bernstein CN (2010) Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities. J Rheumatol Suppl 85:2–10. https://doi.org/10.3899/jrheum.091461
Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S, American Gastroenterological Association Institute Clinical Guidelines C (2017) American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology 153:827–834. https://doi.org/10.1053/j.gastro.2017.07.032
Fischer C, Klotz U (1980) Is plasma level monitoring of sulfasalazine indicated in the treatment of Crohn’s disease or ulcerative colitis? Ther Drug Monit 2:153–158. https://doi.org/10.1097/00007691-198004000-00009
Francès C, Cosnes A, Duhaut P, Zahr N, Soutou B, Ingen-Housz-Oro S, Bessis D, Chevrant-Breton J, Cordel N, Lipsker D, Costedoat-Chalumeau N (2012) Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol 148:479–484. https://doi.org/10.1001/archdermatol.2011.2558
French JK, Hurst NP, O’Donnell ML, Betts WH (1987) Uptake of chloroquine and hydroxychloroquine by human blood leucocytes in vitro: relation to cellular concentrations during antirheumatic therapy. Ann Rheum Dis 46:42–45. https://doi.org/10.1136/ard.46.1.42
Friedman B, Cronstein B (2019) Methotrexate mechanism in treatment of rheumatoid arthritis. Joint Bone Spine 86:301–307. https://doi.org/10.1016/j.jbspin.2018.07.004
Furst DE (1996) Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus 5(Suppl 1):S11-15
Garcia-Carrasco M, Mendoza-Pinto C, Macias-Diaz S, Etchegaray-Morales I, Mendez-Martinez S, Soto-Santillan P, Perez-Romano B, Jimenez-Herrera EA, Guzman-Ruiz O, Ruiz-Arguelles A (2017) Clinical relevance of P-glycoprotein activity on peripheral blood mononuclear cells and polymorphonuclear neutrophils to methotrexate in systemic lupus erythematosus patients. Clin Rheumatol 36:2267–2272. https://doi.org/10.1007/s10067-017-3728-0
Giraud C, Manceau S, Treluyer JM (2010) ABC transporters in human lymphocytes: expression, activity and role, modulating factors and consequences for antiretroviral therapies. Expert Opin Drug Metab Toxicol 6:571–589. https://doi.org/10.1517/17425251003601953
Haines ML, Ajlouni Y, Irving PM, Sparrow MP, Rose R, Gearry RB, Gibson PR (2011) Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm Bowel Dis 17:1301–1307. https://doi.org/10.1002/ibd.21458
Hebing RC, Lin M, Bulatovic Calasan M, Muller IB, Mahmoud S, Heil S, Struys EA, van den Bemt BJ, Twisk JW, Lems W, Nurmohamed MT, Jansen G, de Jonge R (2022) Pharmacokinetics of oral and subcutaneous methotrexate in red and white blood cells in patients with early rheumatoid arthritis: the methotrexate monitoring trial. Ann Rheum Dis. https://doi.org/10.1136/ard-2022-223398
Herman S, Zurgil N, Deutsch M (2005) Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines. Inflamm Res 54:273–280. https://doi.org/10.1007/s00011-005-1355-8
Hopkins AM, Moghaddami M, Foster DJ, Proudman SM, Upton RN, Wiese MD (2017) Intracellular CD3+ T lymphocyte teriflunomide concentration is poorly correlated with and has greater variability than unbound plasma teriflunomide concentration. Drug Metab Dispos 45:8–16. https://doi.org/10.1124/dmd.116.071985
Hoxha A, Calligaro A, Tonello M, Ramonda R, Carletto A, Paolazzi G, Bortolotti R, Del Ross T, Grava C, Boaretto M, Favaro M, Teghil V, Ruffatti A, Punzi L (2016) The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: a prospective multicentre study. Joint Bone Spine 83:167–171. https://doi.org/10.1016/j.jbspin.2015.04.020
Hsueh MF, Bolognesi MP, Wellman SS, Kraus VB (2020) Anti-inflammatory effects of naproxen sodium on human osteoarthritis synovial fluid immune cells. Osteoarthritis Cartilage 28:639–645. https://doi.org/10.1016/j.joca.2020.01.013
Huerta-Garcia AP, Rodriguez-Baez AS, Medellin-Garibay SE, Portales-Perez DP, Martinez-Martinez MU, Abud-Mendoza C, Herrera-Van Oostdam D, Romano-Moreno S, Milan-Segovia RDC (2021) Methotrexate triglutamate as a determinant of clinical response in Mexican patients with rheumatoid arthritis: pharmacokinetics and dose recommendation. J Clin Pharmacol 61:1118–1130. https://doi.org/10.1002/jcph.1837
Irving PM, Gecse KB (2022) Optimizing therapies using therapeutic drug monitoring: current strategies and future perspectives. Gastroenterology 162:1512–1524. https://doi.org/10.1053/j.gastro.2022.02.014
Jani M, Chinoy H, Warren RB, Griffiths CE, Plant D, Fu B, Morgan AW, Wilson AG, Isaacs JD, Hyrich K, Barton A (2015) Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. Arthritis Rheumatol 67:2011–2019. https://doi.org/10.1002/art.39169
Kang JS, Lee MH (2009) Overview of therapeutic drug monitoring. Korean J Intern Med 24:1–10. https://doi.org/10.3904/kjim.2009.24.1.1
Klotz U (1985) Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokinet 10:285–302. https://doi.org/10.2165/00003088-198510040-00001
Korell J, Duffull SB, Dalrymple JM, Drake J, Zhang M, Barclay ML, Stamp LK (2014) Comparison of intracellular methotrexate kinetics in red blood cells with the kinetics in other cell types. Br J Clin Pharmacol 77:493–497. https://doi.org/10.1111/bcp.12209
Krieckaert C, Hernández-Breijo B, Gehin JE, Le Mélédo G, Balsa A, Jani M, Mulleman D, Navarro-Compan V, Wolbink G, Isaac J, van Tubergen A (2022) Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider. RMD Open. https://doi.org/10.1136/rmdopen-2022-002216
Krieckaert CL, van Tubergen A, Gehin JE, Hernández-Breijo B, Le Mélédo G, Balsa A, Böhm P, Cucnik S, Elkayam O, Goll GL, Hooijberg F, Jani M, Kiely PD, McCarthy N, Mulleman D, Navarro-Compán V, Payne K, Perry ME, Plasencia-Rodriguez C, Stones SR, Syversen SW, de Vries A, Ward KM, Wolbink G, Isaacs JD (2023) EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis 82:65–73. https://doi.org/10.1136/annrheumdis-2022-222155
Lemaitre F, Antignac M, Verdier MC, Bellissant E, Fernandez C (2013) Opportunity to monitor immunosuppressive drugs in peripheral blood mononuclear cells: where are we and where are we going? Pharmacol Res 74:109–112. https://doi.org/10.1016/j.phrs.2013.06.003
Lemaitre F, Blanchet B, Latournerie M, Antignac M, Houssel-Debry P, Verdier MC, Dermu M, Camus C, Le Priol J, Roussel M, Zheng Y, Fillatre P, Curis E, Bellissant E, Boudjema K, Fernandez C (2015) Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cells. Clin Biochem 48:406–411. https://doi.org/10.1016/j.clinbiochem.2014.12.018
Lemaitre F, Vethe NT, D’Avolio A, Tron C, Robertsen I, De Winter B, Denicolo A, Koch BCP, Venkataramanan R, Van Gelder T, Brunet M, Bergan S, Hesselink DA, Wallemacq P (2020) Measuring intracellular concentrations of calcineurin inhibitors: expert consensus from the international association of therapeutic drug monitoring and clinical toxicology expert panel. Ther Drug Monit 42:665–670. https://doi.org/10.1097/ftd.0000000000000780
Llorente L, Richaud-Patin Y, Díaz-Borjón A, Alvarado de la Barrera C, Jakez-Ocampo J, de la Fuente H, Gonzalez-Amaro R, Diaz-Jouanen E (2000) Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part I: increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome. Joint Bone Spine 67:30–39
Lowry PW, Franklin CL, Weaver AL, Pike MG, Mays DC, Tremaine WJ, Lipsky JJ, Sandborn WJ (2001) Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 49:665–670. https://doi.org/10.1136/gut.49.5.665
Luster AD, Alon R, von Andrian UH (2005) Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol 6:1182–1190. https://doi.org/10.1038/ni1275
Maksimovic V, Pavlovic-Popovic Z, Vukmirovic S, Cvejic J, Mooranian A, Al-Salami H, Mikov M, Golocorbin-Kon S (2020) Molecular mechanism of action and pharmacokinetic properties of methotrexate. Mol Biol Rep 47:4699–4708. https://doi.org/10.1007/s11033-020-05481-9
Miller DR, Fiechtner JJ, Carpenter JR, Brown RR, Stroshane RM, Stecher VJ (1987) Plasma hydroxychloroquine concentrations and efficacy in rheumatoid arthritis. Arthritis Rheum 30:567–571. https://doi.org/10.1002/art.1780300512
Mok CC (2017) Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus. Expert Rev Clin Immunol 13:35–41. https://doi.org/10.1080/1744666x.2016.1212659
Mok CC, Penn HJ, Chan KL, Tse SM, Langman LJ, Jannetto PJ (2016) Hydroxychloroquine serum concentrations and flares of systemic lupus erythematosus: a longitudinal cohort analysis. Arthritis Care Res (Hoboken) 68:1295–1302. https://doi.org/10.1002/acr.22837
Morinobu A (2020) JAK inhibitors for the treatment of rheumatoid arthritis. Immunol Med 43:148–155. https://doi.org/10.1080/25785826.2020.1770948
Pawlik A, Baskiewicz-Masiuk M, Machalinski B, Gawronska-Szklarz B (2005) The effect of methotrexate and glucocorticosteroids on apoptosis of phythemaglutinin-stimulated mononuclear cells from peripheral blood. Fundam Clin Pharmacol 19:81–85. https://doi.org/10.1111/j.1472-8206.2004.00309.x
Pea F (2018) Intracellular pharmacokinetics of antibacterials and their clinical implications. Clin Pharmacokinet 57:177–189. https://doi.org/10.1007/s40262-017-0572-y
Plosker GL, Croom KF (2005) Sulfasalazine: a review of its use in the management of rheumatoid arthritis. Drugs 65:1825–1849. https://doi.org/10.2165/00003495-200565130-00008
Priyadarssini M, Divya Priya D, Indhumathi S, Rajappa M, Chandrashekar L, Thappa DM (2016) Immunophenotyping of T cells in the peripheral circulation in psoriasis. Br J Biomed Sci 73:174–179. https://doi.org/10.1080/09674845.2016.1207869
Priyadarssini M, Chandrashekar L, Rajappa M (2019) Effect of methotrexate monotherapy on T-cell subsets in the peripheral circulation in psoriasis. Clin Exp Dermatol 44:491–497. https://doi.org/10.1111/ced.13795
Rains CP, Noble S, Faulds D (1995) Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs 50:137–156. https://doi.org/10.2165/00003495-199550010-00009
Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF (2015) Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 23:231–269. https://doi.org/10.1007/s10787-015-0239-y
Rawdha T, Aicha BT, Lobna BA, Issam S, Mouna BS, Olfa S, Selma B, Takoua BB, Kawther BA, Leila M, Hana S, Ines M, Leila A (2022) Therapeutic drug monitoring of teriflunomide: do plasma concentrations predict response to leflunomide in patients with rheumatoid arthritis? Drug Metab Pers Ther. https://doi.org/10.1515/dmpt-2021-0236
Restellini S, Afif W (2021) Update on TDM therapeutic drug monitoring with ustekinumab, vedolizumab and tofacitinib in inflammatory bowel disease. J Clin Med. https://doi.org/10.3390/jcm10061242
Sallustio BC (2021) Monitoring intra-cellular tacrolimus concentrations in solid organ transplantation: use of peripheral blood mononuclear cells and graft biopsy tissue. Front Pharmacol 12:733285. https://doi.org/10.3389/fphar.2021.733285
Schmidt A, Schwind B, Gillich M, Brune K, Hinz B (2003) Simultaneous determination of leflunomide and its active metabolite, A77 1726, in human plasma by high-performance liquid chromatography. Biomed Chromatogr 17:276–281. https://doi.org/10.1002/bmc.244
Schrezenmeier E, Dorner T (2020) Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 16:155–166. https://doi.org/10.1038/s41584-020-0372-x
Sergeant JC, Hyrich KL, Anderson J, Kopec-Harding K, Hope HF, Symmons DPM, Barton A, Verstappen SMM (2018) Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS). Arthritis Res Ther 20:147. https://doi.org/10.1186/s13075-018-1645-5
Stamp LK, Barclay M (2013) Therapeutic drug monitoring in rheumatic diseases: utile or futile? Rheumatology 53:988–997. https://doi.org/10.1093/rheumatology/ket355
Swierkot J, Miedzybrodzki R, Szymaniec S, Szechinski J (2004) Activation dependent apoptosis of peripheral blood mononuclear cells from patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 63:599–600. https://doi.org/10.1136/ard.2003.015370
Taggart AJ, McDermott B, Delargy M, Elborn S, Forbes J, Roberts SD, Ahnfelt NO (1987) The pharmacokinetics of sulphasalazine in young and elderly patients with rheumatoid arthritis. Scand J Rheumatol Suppl 64:29–36. https://doi.org/10.3109/03009748709096719
Takahashi C, Kaneko Y, Okano Y, Taguchi H, Oshima H, Izumi K, Yamaoka K, Takeuchi T (2017) Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study. RMD Open 3:e000363. https://doi.org/10.1136/rmdopen-2016-000363
Tett SE, Cutler DJ, Beck C, Day RO (2000) Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis–a prospective, dose ranging study. J Rheumatol 27:1656–1660
Tsujimura S, Saito K, Nakayamada S, Nakano K, Tanaka Y (2005) Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus. Arthritis Rheum 52:1676–1683. https://doi.org/10.1002/art.21032
Tsujimura S, Saito K, Nawata M, Nakayamada S, Tanaka Y (2008) Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Ann Rheum Dis 67:380–388. https://doi.org/10.1136/ard.2007.070821
Ungar B, Malickova K, Hanžel J, Abu Arisha M, Paul S, Rocha C, Ben Shatach Z, Abitbol CM, Haj Natour O, Selinger L, Yavzori M, Fudim E, Picard O, Shoval I, Eliakim R, Kopylov U, Magro F, Roblin X, Chowers Y, Drobne D, Lukas M, Ben Horin S (2021) Dose optimisation for loss of response to vedolizumab- pharmacokinetics and immune mechanisms. J Crohns Colitis 15:1707–1719. https://doi.org/10.1093/ecco-jcc/jjab067
Vande Casteele N, Herfarth H, Katz J, Falck-Ytter Y, Singh S (2017) American gastroenterological association institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases. Gastroenterology 153:835-857.e836. https://doi.org/10.1053/j.gastro.2017.07.031
van den Bemt BJ, den Broeder AA, Wolbink GJ, van den Maas A, Hekster YA, van Riel PL, Benraad HB, van den Hoogen FH (2013) The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis. Br J Clin Pharmacol 76:939–945. https://doi.org/10.1111/bcp.12142
van Haandel L, Leeder JS, Becker ML (2011) Measurement of methotrexate metabolites in peripheral blood mononuclear cells in juvenile idiopathic arthritis: a more relevant cellular biomarker for drug response? Arthritis Rheum 63:S95
Van Herwaarden N, Van Den Bemt BJF, Wientjes MHM, Kramers C, Den Broeder AA (2017) Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review. Expert Opin Drug Metab Toxicol 13:843–857. https://doi.org/10.1080/17425255.2017.1353602
van Roon EN, Jansen TL, van de Laar MA, Janssen M, Yska JP, Keuper R, Houtman PM, Brouwers JR (2005) Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 64:569–574. https://doi.org/10.1136/ard.2004.025205
Vikingsson S, Carlsson B, Almer S, Peterson C (2010) How should thiopurine treatment be monitored?–methodological aspects. Nucleosides Nucleotides Nucleic Acids 29:278–283. https://doi.org/10.1080/15257771003741133
Wessels JAM, Huizinga TWJ, Guchelaar HJ (2007) Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology 47:249–255. https://doi.org/10.1093/rheumatology/kem279
Wilson L, Tuson S, Yang L, Loomes D (2021) Real-world use of azathioprine metabolites changes clinical management of inflammatory bowel disease. J Can Assoc Gastroenterol 4:101–109. https://doi.org/10.1093/jcag/gwaa005
Wyant T, Fedyk E, Abhyankar B (2016) An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis 10:1437–1444. https://doi.org/10.1093/ecco-jcc/jjw092
Funding
There are no funding sources.
Author information
Authors and Affiliations
Contributions
Dao-Hai Cheng conceived and wrote the paper. Zhen-Guang Huang reviewed and edited the manuscript. Both authors read and approved the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that there are no conflicts of interest.
Ethical approval
Not applicable.
Consent to participate
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Cheng, DH., Huang, ZG. Therapeutic drug monitoring of disease-modifying antirheumatic drugs in circulating leukocytes in immune-mediated inflammatory diseases. Inflammopharmacol 31, 1789–1811 (2023). https://doi.org/10.1007/s10787-023-01243-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10787-023-01243-8